Figure 6—figure supplement 1

Figure 6—figure supplement 1

(A) Bright-field single-plane images of control MO (6 ng), 1/2x or 1/5x sqt (1 or 0.4 ng, respectively) + cyc (2 or 0.8 ng, respectively) MO YSL-injected embryos at pharyngula stage (32 hpf). The proportion of embryos with a phenotype similar to the images shown is indicated in the lower right corner (control: n = 19, N = 2; 1/2x sqt/cyc: n = 21, N = 2 and 1/5x sqt/cyc: n = 22, N = 2). The control MO samples are also shown in Figure 5B. (B) Expression of sox32, an endoderm marker gene, as determined by whole mount in situ hybridization in control MO (6 ng) or 1/5x sqt (0.4 ng) + cyc (0.8 ng) MO YSL-injected embryos (side views) at bud stage. Embryos are shown as an animal view (schematic representation shown on the left). The proportion of embryos with a phenotype similar to the images shown is indicated in the lower right corner (control MO: n = 33, N = 3 and 1/5x sqt/cyc: n = 30, N = 3). (C) Percentage of bud stage control MO (n = 33, N = 3) or 1/5x sqt (0.4 ng) + cyc (0.8 ng) MO YSL-injected embryos (n = 30, N = 3) showing normal, strongly reduced or no expression of sox32, as determined by whole mount in situ hybridization. (D) High-resolution images of control MO (6 ng) or 1/5x sqt (0.4 ng) + cyc (0.8 ng) MO YSL-injected embryos expressing gsc::GFP-CAAX and H2B-EGFP (injection control) at 50% epiboly (dorsal domain: control, n = 11, N = 5; sqt/cyc, n = 8, N = 3; lateral domain: control, n = 9, N = 4; sqt/cyc, n = 7, N = 3). The position along the dorsal-ventral axis is indicated at the top. Images correspond to the embryos also shown in Figure 6D. Scale bars: 500 µm (A), 200 µm (B), 100 µm (C).

Figure 6—figure supplement 1—source data 1.